BioNTech

BNTX

Market cap $23.9B

Overview Fund Activity

99.26 USD

+1.38

1.41%

At close Updated Sep 16, 4:00 PM EDT

Pre-market

After hours

99.18

-0.08

0.08%

1 day

1.41%

5 days

-2.53%

1 month

-11.81%

3 months

-6.65%

6 months

-1.59%

Year to date

-13.91%

1 year

-19.61%

5 years

50.3%

10 years

597.05%

About: BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.

Employees: 6,772

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

21% more capital invested

Capital invested by funds: $4.71B [Q1] → $5.72B (+$1.01B) [Q2]

2% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 82

0.79% more ownership

Funds ownership: 21.57% [Q1] → 22.36% (+0.79%) [Q2]

8% less funds holding

Funds holding: 277 [Q1] → 256 (-21) [Q2]

17% less call options, than puts

Call options by funds: $150M | Put options by funds: $180M

20% less funds holding in top 10

Funds holding in top 10: 5 [Q1] → 4 (-1) [Q2]

36% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 50

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$133

34% upside

Avg. target

$138

39% upside

High target

$150

51% upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Robert Burns	$136	Buy Reiterated	8 Sep 2025
Wells Fargo Mohit Bansal	$150	Overweight Maintained	5 Aug 2025
B of A Securities Tazeen Ahmad	$134	Buy Maintained	5 Aug 2025
Morgan Stanley Terence Flynn	$133	Overweight Maintained	10 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 16 articles about BNTX published over the past 30 days

Zacks Investment Research

COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths

MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.

COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths

The Motley Fool

Why BioNTech Stock Sank by More Than 7% Today

A star stock during the pandemic era wasn't shining so brightly on Friday. On a media report that the current presidential administration is preparing to link a set of fatalities to Covid vaccines, BioNTech's (BNTX -7.35%) share price declined by 7% across that day's trading session.

Why BioNTech Stock Sank by More Than 7% Today

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

Zacks Investment Research

BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?

Bristol Myers and BioNTech report strong mid-stage lung cancer trial data for pumitamig, showing high response rates and manageable safety.

BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BioNTech SE BNTX and Bristol Myers Squibb Co BMY shared interim Phase 2 data on pumitamig (BNT327/BMS986545) plus chemotherapy in patients with untreated extensive-stage small cell lung cancer (ES-SCLC).

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

A next-generation cancer immunotherapy by BioNTech and partner Bristol Myers Squibb led to encouraging tumour shrinkage in a mid-stage trial on small cell lung cancer that has started spreading, the German biotech firm said on Monday.

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

MAINZ, Germany, and PRINCETON, USA, September 8, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today presented interim data from a global randomized Phase 2 trial (NCT06449209) evaluating pumitamig (also known as BNT327 or BMS986545), an investigational bispecific antibody targeting PD-L1 x VEGF-A, plus chemotherapy in patients with extensive-stage small cell lung cancer (“ES-SCLC”). The data, which are consistent with data presented at the European Lung Cancer Congress (“ELCC”) 2025 from a Phase 2 trial conducted in China (NCT05844150), showed encouraging anti-tumor responses with a positive trend in the secondary endpoint progression free survival. Pumitamig plus chemotherapy demonstrated a manageable safety profile with no new safety signals and a low discontinuation rate. The data are being presented today as a late-breaker oral presentation at the IASLC 2025 World Conference on Lung Cancer (“WCLC”) hosted by the International Association for the Study of Lung Cancer in Barcelona.

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Pfizer, partner BioNTech say updated COVID shot shows better immune response

Pfizer and partner BioNTech said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one underlying risk condition.

Pfizer, partner BioNTech say updated COVID shot shows better immune response

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced positive topline results from an ongoing Phase 3 clinical trial cohort evaluating the safety, tolerability, and immunogenicity of a 30-µg dose of the LP.8.1-adapted monovalent COMIRNATY® (COVID-19 Vaccine, mRNA) 2025-2026 Formula in adults aged 65 and older and in adults aged 18 through 64 with at least one underlying risk condition for severe COVID-19. The pr.

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

The Motley Fool

Why BioNTech Stock Crushed the Market Today

BioNTech (BNTX 8.62%), the Germany-based biotech that scored big early in the pandemic era with the Comirnaty vaccine it developed with Pfizer, had some fresh news from the lab to report on Friday. Investors clearly liked what they heard, as they traded up the German biotech's American depositary receipts (ADRs) by 10% that day.

Why BioNTech Stock Crushed the Market Today

See News Rankings

Charts implemented using Lightweight Charts™